Live Breaking News & Updates on Rare Tumor Program

Stay updated with breaking news from Rare tumor program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in .
Oxurion NVApril 12, 2021 GMT
Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Association for Cancer Research (AACR).  
The data was presented by Dr. Giselle Sholler, Director, Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Paediatric Oncology at the Levine Children’s Hospital in Charlotte, NC. ....

United States , Region Flamande , Elisabeth Stes , Rakesh Jain , Peter Carmeliet , Wouter Piepers , Giselle Sholler , Sylvie Berrebi Frazer Hall , Citigate Dewe Rogerson , Isabella Santos Foundation Solid , Hasselt University , Ghent University , Rare Tumor Program , Beat Childhood Cancer Research Consortium , American Association For Cancer Research , Atrium Health Levine Children Hospital , Corporate Communications , University Of Antwerp , American Association , Cancer Research , Paediatric Oncology , Levine Children , Ewing Sarcoma , Massachusetts General Hospital , Atrium Health Levine Children , Prof Rakesh Jain ,

ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer .
Oxurion NVApril 9, 2021 GMT
Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB)
Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses 
Leuven, Belgium 9th April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that it will make two presentations at the upcoming AACR Virtual Annual Meeting 2021 which will take place from 9 to 14 April. ....

Region Flamande , Bruxelles Capitale , Joa Van Ginderachter , Elisabeth Stes , Damya Laoui , Pascal Merchiers , Heleen Roose , Elizabeth Allen , Rosa Mart , Sylvie Berrebi Frazer Hall , Bruno Dombrecht , Wouter Piepers , Helena Van Damme , Giselle Sholler , Citigate Dewe Rogerson , Isabella Santos Foundation Solid , Hasselt University , Discovery Sciences , Ghent University , Rare Tumor Program , Myeloid Cell Immunology Lab , Beat Childhood Cancer Research Consortium , Inflammation Research , Corporate Communications , University Of Antwerp , Laboratory Of Cellular ,